Laboratory #Corp. of #America Holdings (LH) Shares #Sold by #Ameriprise #Financial Inc.

Ameriprise Financial Inc. trimmed its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 30.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,233 shares of the medical research company’s stock after selling 38,471 shares during the quarter. Ameriprise Financial Inc. owned about 0.09% of Laboratory Corp. of America worth $13,320,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Acrospire Investment Management LLC boosted its holdings in Laboratory Corp. of America by 16.5% in the second quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 100 shares in the last quarter. Sun Life Financial INC boosted its holdings in shares of Laboratory Corp. of America by 9,200.0% in the second quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 736 shares during the period. IFP Advisors Inc boosted its holdings in shares of Laboratory Corp. of America by 83.9% in the second quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after acquiring an additional 523 shares during the period. Hourglass Capital LLC acquired a new stake in shares of Laboratory Corp. of America in the second quarter valued at approximately $200,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Laboratory Corp. of America in the third quarter valued at approximately $210,000. 91.46% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on LH. Barclays reissued a “buy” rating and issued a $195.00 price objective on shares of Laboratory Corp. of America in a report on Wednesday. Mizuho set a $165.00 price objective on Laboratory Corp. of America and gave the company a “neutral” rating in a report on Friday, December 1st. ValuEngine raised Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. Jefferies Group set a $167.00 price objective on Laboratory Corp. of America and gave the company a “hold” rating in a report on Friday, November 24th. Finally, Zacks Investment Research downgraded Laboratory Corp. of America from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $171.33.

Laboratory Corp. of America Holdings (NYSE:LH) traded up $3.22 during trading on Friday, hitting $159.06. The stock had a trading volume of 892,416 shares, compared to its average volume of 643,371. Laboratory Corp. of America Holdings has a twelve month low of $126.44 and a twelve month high of $164.22. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.89 and a quick ratio of 1.75. The stock has a market capitalization of $16,192.31, a PE ratio of 17.10, a PEG ratio of 1.69 and a beta of 0.87.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.08. Laboratory Corp. of America had a return on equity of 16.75% and a net margin of 7.40%. The business had revenue of $2.60 billion during the quarter, compared to analysts’ expectations of $2.55 billion. During the same quarter in the prior year, the business earned $2.25 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. sell-side analysts expect that Laboratory Corp. of America Holdings will post 9.52 EPS for the current fiscal year.

In other news, Director Dwight Gary Gilliland sold 971 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $153.52, for a total transaction of $149,067.92. Following the completion of the sale, the director now owns 3,501 shares in the company, valued at $537,473.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.90% of the stock is owned by corporate insiders.

Leave a Reply

Your email address will not be published. Required fields are marked *